Zimmer Biomet Holdings Receives a Buy from RBC Capital

By Ryan Adsit

RBC Capital analyst Glenn Novarro reiterated a Buy rating on Zimmer Biomet Holdings (NYSE: ZBH) today and set a price target of $130. The company’s shares closed yesterday at $105.40.

According to TipRanks.com, Novarro is a 1-star analyst with an average return of -1.8% and a 45.0% success rate. Novarro covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Boston Scientific Corp., and Baxter International.

Currently, the analyst consensus on Zimmer Biomet Holdings is Strong Buy and the average price target is $141.67, representing a 34.4% upside.

In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock.

Zimmer Biomet Holdings’ market cap is currently $21.05B and has a P/E ratio of 172.79. The company has a book value ratio of 2.2044.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2016, Daniel Williamson, the Group President of ZBH sold 2,716 shares for a total of $352,944.

Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products; sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. It operates through three major geographic segments: America, Europe and Asia Pacific. The Americas segment comprises principally of the U.S. and includes other North, Central and South American markets. The Europe segment comprises principally of Europe and includes the Middle East and African markets. The Asia Pacific segment comprises primarily of Japan and includes other Asian and Pacific markets. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.